| scholarly article | Q13442814 |
| P50 | author | Łukasz Skalniak | Q60594412 |
| Ewa Surmiak | Q88496745 | ||
| Justyna Kocik | Q89733187 | ||
| Monika Machula | Q92084373 | ||
| Aneta Wisniewska | Q92084377 | ||
| P2093 | author name string | Tad A Holak | |
| P2860 | cites work | DNA topoisomerases: structure, function, and mechanism | Q22065417 |
| Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain | Q24314763 | ||
| A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma | Q52714998 | ||
| Transient activation of p53 in G2 phase is sufficient to induce senescence. | Q53043642 | ||
| Inhibition of miR-17 and miR-20a by oridonin triggers apoptosis and reverses chemoresistance by derepressing BIM-S. | Q53539712 | ||
| Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2. | Q53634741 | ||
| Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses | Q53963822 | ||
| MEK'ing the Most of p53 Reactivation Therapy in Melanoma | Q54536549 | ||
| Zinc Metallochaperones as Mutant p53 Reactivators: A New Paradigm in Cancer Therapeutics. | Q55471290 | ||
| Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors | Q57066266 | ||
| Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells | Q57790455 | ||
| The combination of Nutlin-3 and Tanshinone IIA promotes synergistic cytotoxicity in acute leukemic cells expressing wild-type p53 by co-regulating MDM2-P53 and the AKT/mTOR pathway | Q58592185 | ||
| Contribution of genotoxic anticancer treatments to the development of multiple primary tumours in the context of germline TP53 mutations | Q58669670 | ||
| CDK4 inhibition diminishes p53 activation by MDM2 antagonists | Q58751929 | ||
| MDM2- and FLT3-inhibitors in the treatment of -ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin | Q59810103 | ||
| Apoptosis and apoptotic body: disease message and therapeutic target potentials | Q61446208 | ||
| Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in wild-type Ewing sarcoma | Q61570969 | ||
| CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101 | Q61863426 | ||
| Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma | Q64237646 | ||
| Comparison of genotoxic versus nongenotoxic stabilization of p53 provides insight into parallel stress-responsive transcriptional networks | Q64268010 | ||
| Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53-independent pancreatic cancer cell death | Q64386413 | ||
| Divergent Dynamics and Functions of ERK MAP Kinase Signaling in Development, Homeostasis and Cancer: Lessons from Fluorescent Bioimaging. | Q64955704 | ||
| Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs | Q73002431 | ||
| Tyrosine kinases as targets for cancer therapy | Q80367757 | ||
| Targeted cancer therapies | Q83066772 | ||
| A tale of two antibodies: obinutuzumab versus rituximab | Q88613934 | ||
| Tolerability of obinutuzumab therapy in patients with rituximab-relapsed/refractory B-cell malignancies - a retrospective single center cohort study | Q90455044 | ||
| ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma | Q90706191 | ||
| A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours | Q90750992 | ||
| A therapeutic patent overview of MDM2/X-targeted therapies (2014-2018) | Q92042307 | ||
| Rucaparib: A Review in Ovarian Cancer | Q92106789 | ||
| Combinatorial Therapy of Zinc Metallochaperones with Mutant p53 Reactivation and Diminished Copper Binding | Q92731843 | ||
| Identification and characterization of a new member of the TNF family that induces apoptosis | Q24318423 | ||
| Death Receptor 5, a New Member of the TNFR Family, and DR4 Induce FADD-Dependent Apoptosis and Activate the NF-κB Pathway | Q24320210 | ||
| Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family | Q24320301 | ||
| The DNA-damage response in human biology and disease | Q24606586 | ||
| Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance | Q24645668 | ||
| Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family | Q24670396 | ||
| Tyrosine kinase - Role and significance in Cancer. | Q24791430 | ||
| Onto better TRAILs for cancer treatment | Q26768160 | ||
| Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective | Q26796455 | ||
| Antibody-based immunotherapy of solid cancers: progress and possibilities | Q26796542 | ||
| Roscovitine in cancer and other diseases | Q26799874 | ||
| Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review | Q26850912 | ||
| Genotoxic anti-cancer agents and their relationship to DNA damage, mitosis, and checkpoint adaptation in proliferating cancer cells | Q26851196 | ||
| How cell death shapes cancer | Q27021441 | ||
| In vitro selection of mutant HDM2 resistant to Nutlin inhibition | Q27322456 | ||
| In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 | Q27642888 | ||
| Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development | Q27643965 | ||
| The central valine concept provides an entry in a new class of non peptide inhibitors of the p53-MDM2 interaction | Q27678563 | ||
| ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets | Q27683708 | ||
| Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development | Q27684199 | ||
| Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development | Q27685122 | ||
| Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers | Q27685364 | ||
| Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors | Q27701564 | ||
| Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument | Q27727716 | ||
| Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition | Q28115131 | ||
| Protein kinase C (PKC) family in cancer progression | Q28252013 | ||
| Following a TRAIL: update on a ligand and its five receptors | Q28292767 | ||
| Tumor suppressor p53 is a direct transcriptional activator of the human bax gene | Q28306186 | ||
| Actinomycin D induces apoptosis and inhibits growth of pancreatic cancer cells | Q28376530 | ||
| Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme | Q28477660 | ||
| Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). | Q37221909 | ||
| Cell fate decision mediated by p53 pulses | Q37262599 | ||
| Actinomycin D enhances killing of cancer cells by immunotoxin RG7787 through activation of the extrinsic pathway of apoptosis | Q37281460 | ||
| Targeting the PI3K-AKT-mTOR signaling network in cancer | Q37353968 | ||
| Death receptor signal transducers: nodes of coordination in immune signaling networks | Q37417486 | ||
| Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer. | Q37457809 | ||
| Evaluation of zinc (II) chelators for inhibiting p53-mediated apoptosis | Q37589145 | ||
| State of the art in anti-cancer mAbs. | Q37655585 | ||
| Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia. | Q37688589 | ||
| V-ATPase inhibition increases cancer cell stiffness and blocks membrane related Ras signaling - a new option for HCC therapy | Q37705990 | ||
| p53-based cancer therapy | Q37750115 | ||
| Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells. | Q37761824 | ||
| Managing the adverse effects of radiation therapy. | Q37779542 | ||
| The missing Zinc: p53 misfolding and cancer | Q37808944 | ||
| p63/p73 in the control of cell cycle and cell death. | Q37983307 | ||
| Protein kinase C and cancer: what we know and what we do not. | Q38171231 | ||
| Drugging the p53 pathway: understanding the route to clinical efficacy | Q38191796 | ||
| Targeting PI3K/Akt/mTOR Signaling in Cancer | Q38208314 | ||
| Obinutuzumab: a new class of anti-CD20 monoclonal antibody. | Q38228447 | ||
| Could valproic acid be an effective anticancer agent? The evidence so far. | Q38228823 | ||
| PARP inhibitors: A new era of targeted therapy | Q38364532 | ||
| The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy. | Q38397326 | ||
| Cyclin dependent kinase (CDK) inhibitors as anticancer drugs | Q38538675 | ||
| ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development | Q38640917 | ||
| Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression | Q38676063 | ||
| Oridonin synergizes with Nutlin-3 in osteosarcoma cells by modulating the levels of multiple Bcl-2 family proteins | Q38700198 | ||
| Radiosensitization of adenoid cystic carcinoma with MDM2 inhibition. | Q38703939 | ||
| The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53 - p21 - Rb - E2F1 Cascade in the p53wildtype Neuroendocrine Tumor Cell Line GOT1. | Q38729808 | ||
| Combine and conquer: challenges for targeted therapy combinations in early phase trials. | Q38734451 | ||
| The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression | Q38756911 | ||
| Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388). | Q38784989 | ||
| Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients | Q38793389 | ||
| The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches | Q38825614 | ||
| Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma. | Q41609825 | ||
| Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf-/- mouse model. | Q41710165 | ||
| Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL. | Q42037754 | ||
| The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. | Q42064781 | ||
| Dynamics of targeted cancer therapy | Q42197906 | ||
| Receptor Tyrosine Kinases: Role in Cancer Progression | Q42233483 | ||
| Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer | Q42378380 | ||
| Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53. | Q42722283 | ||
| Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells | Q42970606 | ||
| Perifosine plus nutlin-3 combination shows a synergistic anti-leukaemic activity | Q43230777 | ||
| TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications | Q43684721 | ||
| Discontinued drugs in 2012: oncology drugs | Q44178390 | ||
| MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death | Q45862563 | ||
| The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. | Q46544703 | ||
| Inhibition of the Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells | Q46593297 | ||
| Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM. | Q47232697 | ||
| Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma | Q48570977 | ||
| Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma | Q49233795 | ||
| Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets | Q49539698 | ||
| Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies? | Q49601705 | ||
| Metformin and cancer: An existing drug for cancer prevention and therapy | Q50105959 | ||
| Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737 | Q28542684 | ||
| The p53-mdm-2 autoregulatory feedback loop | Q28609811 | ||
| Regulation of PTEN transcription by p53 | Q28646911 | ||
| An inhibitor of Bcl-2 family proteins induces regression of solid tumours | Q29547595 | ||
| p53-dependent apoptosis modulates the cytotoxicity of anticancer agents | Q29615031 | ||
| DNA repair pathways as targets for cancer therapy | Q29615572 | ||
| Discovery of 4-((3'R,4'S,5'R)-6″-Chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2″-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3″-indoline]-5'-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine [...] | Q33572704 | ||
| Heat shock proteins: a review of the molecular chaperones | Q33588946 | ||
| Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML. | Q33597514 | ||
| Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models. | Q33699808 | ||
| WIP1 phosphatase as pharmacological target in cancer therapy. | Q33720757 | ||
| Blockade of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces Apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim. | Q33732534 | ||
| Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas | Q33815063 | ||
| The coordinate regulation of the p53 and mTOR pathways in cells | Q33840457 | ||
| MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer | Q33869257 | ||
| Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199. | Q33875554 | ||
| MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines | Q33915624 | ||
| MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function | Q33930068 | ||
| Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. | Q33999606 | ||
| Multiple p53-independent gene silencing mechanisms define the cellular response to p53 activation | Q34080682 | ||
| Cisplatin in cancer therapy: molecular mechanisms of action | Q34098163 | ||
| Nutlin‐3 enhances sorafenib efficacy in renal cell carcinoma | Q34127380 | ||
| Coordination between Cell Cycle Progression and Cell Fate Decision by the p53 and E2F1 Pathways in Response to DNA Damage | Q34181478 | ||
| Metal chaperones: a holistic approach to the treatment of Alzheimer's disease | Q34260002 | ||
| Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy | Q34478557 | ||
| SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression | Q34584722 | ||
| The resurgence of platinum-based cancer chemotherapy | Q34649255 | ||
| Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor | Q34695283 | ||
| Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21) | Q34982229 | ||
| MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53. | Q34999483 | ||
| Two-phase dynamics of p53 in the DNA damage response. | Q35022037 | ||
| WIP1 phosphatase as a potential therapeutic target in neuroblastoma | Q35058327 | ||
| Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment. | Q35087851 | ||
| Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia | Q35178411 | ||
| Actinomycin D inhibits cell proliferations and promotes apoptosis in osteosarcoma cells | Q35479577 | ||
| HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma | Q35483623 | ||
| The Bcl-2 family: roles in cell survival and oncogenesis. | Q35591695 | ||
| Network Modeling of MDM2 Inhibitor-Oxaliplatin Combination Reveals Biological Synergy in wt-p53 solid tumors | Q35640255 | ||
| Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours | Q35653933 | ||
| Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity | Q35741309 | ||
| Cancer and Radiation Therapy: Current Advances and Future Directions | Q35816527 | ||
| Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives | Q35836881 | ||
| Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia | Q35849887 | ||
| How To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures. | Q35871210 | ||
| Feedbacks, Bifurcations, and Cell Fate Decision-Making in the p53 System | Q35940296 | ||
| Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells | Q35977483 | ||
| Proteasome inhibition in the treatment of cancer | Q36012206 | ||
| Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma | Q36040768 | ||
| Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097 | Q36132787 | ||
| Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model. | Q36359692 | ||
| Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways | Q36361245 | ||
| Intracellular-signaling tumor-regression modeling of the pro-apoptotic receptor agonists dulanermin and conatumumab | Q36366424 | ||
| The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status | Q36366626 | ||
| Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition | Q36499146 | ||
| Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells | Q36544358 | ||
| A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis | Q36678322 | ||
| The mdm-2 gene is induced in response to UV light in a p53-dependent manner | Q36717209 | ||
| Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: a retrospective evaluation | Q36753313 | ||
| The Ras/Raf/MAPK pathway | Q36780542 | ||
| Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib | Q36902184 | ||
| Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90 | Q37044062 | ||
| Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models | Q37045295 | ||
| Proteasome inhibitors in cancer therapy: lessons from the first decade | Q37112347 | ||
| Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo. | Q37118668 | ||
| RG7112, a small-molecule inhibitor of MDM2, enhances trabectedin response in soft tissue sarcomas | Q38842538 | ||
| Nutlin-3 sensitizes nasopharyngeal carcinoma cells to cisplatin-induced cytotoxicity | Q38845519 | ||
| Inhibitors of histone deacetylase as antitumor agents: A critical review | Q38848025 | ||
| The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer | Q38858580 | ||
| Actinomycin D and nutlin-3a synergistically promote phosphorylation of p53 on serine 46 in cancer cell lines of different origin | Q38873167 | ||
| A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097. | Q38876081 | ||
| Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma | Q38890690 | ||
| The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents | Q38922354 | ||
| Oridonin induces apoptosis in uveal melanoma cells by upregulation of Bim and downregulation of Fatty Acid Synthase | Q38924884 | ||
| Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia | Q38989476 | ||
| MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways | Q38997002 | ||
| V-ATPase inhibition regulates anoikis resistance and metastasis of cancer cells. | Q39028592 | ||
| Protein kinase C in cancer: The top five unanswered questions. | Q39098659 | ||
| Pre-activation of the p53 pathway through Nutlin-3a sensitises sarcomas to drozitumab therapy | Q39152554 | ||
| Reviving the guardian of the genome: Small molecule activators of p53. | Q39205536 | ||
| The V-ATPase-inhibitor archazolid abrogates tumor metastasis via inhibition of endocytic activation of the Rho-GTPase Rac1. | Q39276731 | ||
| TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma | Q39439144 | ||
| Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. | Q39446764 | ||
| Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3 | Q39530180 | ||
| Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway | Q39627892 | ||
| Efficacy of MDM2 inhibitor MI-219 against lung cancer cells alone or in combination with MDM2 knockdown, a XIAP inhibitor or etoposide | Q39644697 | ||
| MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity | Q39711027 | ||
| Pharmacologic p53 activation blocks cell cycle progression but fails to induce senescence in epithelial cancer cells | Q39802058 | ||
| Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells | Q39840685 | ||
| MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma. | Q39888339 | ||
| Recurrent initiation: a mechanism for triggering p53 pulses in response to DNA damage. | Q39983426 | ||
| Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination. | Q40048230 | ||
| AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl | Q40093939 | ||
| Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients | Q40123673 | ||
| Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML. | Q40195272 | ||
| Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells. | Q40209862 | ||
| (R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastoma cells to nutlin-3-induced apoptosis | Q40269287 | ||
| Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. | Q40270647 | ||
| MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. | Q40324423 | ||
| Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer | Q40359028 | ||
| AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells | Q40389484 | ||
| AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia | Q40401097 | ||
| Topoisomerase Poisons: Harnessing the Dark Side of Enzyme Mechanism | Q40476934 | ||
| MDM2 antagonist nutlin-3a sensitizes tumors to V-ATPase inhibition | Q40682883 | ||
| TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation | Q40854245 | ||
| An Overview on Radiotherapy: From Its History to Its Current Applications in Dermatology | Q41179839 | ||
| Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists | Q41279899 | ||
| The Many Faces of MDM2 Binding Partners | Q41287020 | ||
| Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma | Q41343291 | ||
| MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomas | Q41553688 | ||
| Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity | Q41561051 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 7 | |
| P577 | publication date | 2019-07-19 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Cancers | Q27722963 |
| P1476 | title | Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists | |
| P478 | volume | 11 |
| Q90590454 | Targeting apoptosis in cancer therapy | cites work | P2860 |
Search more.